1921
Volume 87, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

As a result of widespread antimalarial drug resistance, all African countries with endemic malaria have, in recent years, changed their malaria treatment policy. In Senegal, the health authorities changed from chloroquine (CQ) to a combination of sulfadoxine–pyrimethamine (SP) plus amodiaquine (AQ) in 2003. Since 2006, the artemisinin combination therapies (ACTs) artemether–lumefantrine (AL) and artesunate plus amodiaquine (AS/AQ) were adopted for uncomplicated malaria treatment. After several years of CQ withdrawal, the current study wished to determine the level of CQ resistance at the molecular level in selected sites in Senegal, because the scientific community is interested in using CQ again. Finger prick blood samples were collected from -positive children below the age of 10 years ( = 474) during cross-sectional surveys conducted in two study sites in Senegal with different malaria transmission levels. One site is in central Senegal, and the other site is in the southern part of the country. All samples were analyzed for single nucleotide polymorphisms (SNPs) in the CQ resistance transporter gene (; codons 72–76) using polymerase chain reaction (PCR) sequence-specific oligonucleotide probe (SSOP) enzyme-linked immunosorbent assay (ELISA) and real-time PCR methods. In total, the 72- to 76-codon region of was amplified in 449 blood samples (94.7%; 285 and 164 samples from the central and southern sites of Senegal, respectively). In both study areas, the prevalence of the wild-type single CVMNK haplotype was very high; in central Senegal, the prevalence was 70.5% in 2009 and 74.8% in 2010, and in southern Senegal, the prevalence was 65.4% in 2010 and 71.0% in 2011. Comparing data with older studies in Senegal, a sharp decline in the mutant type prevalence is evident: from 65%, 64%, and 59.5% in samples collected from various sites in 2000, 2001, and 2004 to approximately 30% in our study. A similar decrease in mutant type prevalence is noted in other neighboring countries. With the continued development of increased CQ susceptibility in many African countries, it may be possible to reintroduce CQ in the near future in a drug combination; it could possibly be given to non-vulnerable groups, but it demands close monitoring of possible reemergence of CQ resistance development.

[open-access] This is an Open Access article distributed under the terms of the American Society of Tropical Medicine and Hygiene's Re-use License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2012.11-0709
2012-10-03
2017-09-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/87/4/640.html?itemId=/content/journals/10.4269/ajtmh.2012.11-0709&mimeType=html&fmt=ahah

References

  1. Trape JF, , 2001. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg 64 (1–2 Suppl): 1217.
  2. Trape JF, Pison G, Preziosi MP, Enel C, Desgrees DLA, Delauney V, Samb B, Lagarde E, Molez JF, Simondon F, , 1998. Impact of chloroquine resistance on malaria mortality. C R Acad Sci III 321: 689697.[Crossref]
  3. Gaye O, Soumare M, Sambou B, Faye O, Dieng Y, Diouf M, Bah IB, Dieng T, Ndir O, Diallo S, , 1999. Heterogeneity of chloroquine resistant malaria in Senegal. Bull Soc Pathol Exot 92: 149152.
  4. Botella DMJ, Valls FJM, Martinez PML, Espacio CA, , 1991. Plasmodium falciparum resistant to sulfadoxine/pyrimethamine in Senegal. Med Interna 8: 7981.
  5. Sokhna CS, Trape JF, Robert V, , 2001. Gametocytaemia in Senegalese children with uncomplicated falciparum malaria treated with chloroquine, amodiaquine or sulfadoxine plus pyrimethamine. Parasite 8: 243250.[Crossref]
  6. Brasseur P, Diallo S, Guiguemde R, Guiyedi V, Kombila M, Ringwald P, Olliaro P, , 1999. Amodiaquine remains effective for treating uncomplicated malaria in West and Central Africa. Trans R Soc Trop Med Hyg 93: 645650.[Crossref]
  7. World Health Organization, 2010. Guidelines for the Treatment of Malaria, 2nd Ed. Geneva, Switzerland: WHO Press.
  8. Brasseur P, Agnamey P, Gaye O, Vaillant M, Taylor WR, Olliaro P, , 2007. Efficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern Senegal. Malar J 6: 150.[Crossref]
  9. Roll Back Malaria Partnership, 2010. Roll Back Malaria. Progress and Impact Series: Focus on Senegal. Available at: http://www.rbm.who.int/ProgressImpactSeries/report4.
  10. Ndiaye JL, Faye B, Gueye A, Tine R, Ndiaye D, Tchania C, Ndiaye I, Barry A, Cissé B, Lameyre V, Gaye O, , 2011. Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial. Malar J 10: 237.[Crossref]
  11. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LMB, Sidhu ABS, Naude B, Deitsch KW, Su X-Z, Wootton JC, Roepe PD, Wellems TE, , 2000. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 6: 861871.[Crossref]
  12. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su X-Z, Nomura T, Fidock D, Wellems TE, Plowe CV, , 2001. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 344: 257263.[Crossref]
  13. Chen N, Kyle DE, Pasay C, Fowler EV, Baker J, Peters JM, Cheng Q, , 2003. pfcrt allelic types with two novel amino acid mutations in chloroquineresistant Plasmodium falciparum isolates from the Philippines. Antimicrob Agents Chemother 47: 35003505.[Crossref]
  14. Nagesha HS, Casey GJ, Rieckmann KH, Fryauff DJ, Laksana BS, Reeder JC, Maguire JD, Baird JK, , 2003. New haplotypes of the Plasmodium falciparum chloroquine resistance transporter (pfcrt) gene among chloroquineresistant parasite isolates. Am J Trop Med Hyg 68: 398402.
  15. Hayward R, Saliba KJ, Kirk K, , 2005. Mutations in pfmdr1 modulate the sensitivity of Plasmodium falciparum to the intrinsic antiplasmodial activity of verapamil. Antimicrob Agents Chemother 49: 840842.[Crossref]
  16. Foote S, Kyle D, Martin R, Oduola A, Forsyth K, Kemp D, Cowman A, , 1990. Several alleles of the multidrug resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum . Nature 345: 255258.[Crossref]
  17. Gadalla N, Elzaki SE, Mukhtar E, Warhurst D, Badria El-Sayed, Sutherland CJ, , 2010. Dynamics of pfcrt alleles CVMNK and CVIET in chloroquine-treated Sudanese patients infected with Plasmodium falciparum . Malar J 9: 74.[Crossref]
  18. Sutherland CJ, Haustein T, Gadalla N, Armstrong M, Doherty JF, Chiodini PL, , 2007. Chloroquine-resistant Plasmodium falciparum infections among UK travellers returning with malaria after chloroquine prophylaxis. J Antimicrob Chemother 59: 11971199.[Crossref]
  19. Alifrangis M, Dalgaard MB, Lusingu JP, Vestergaard LS, Staalsoe T, Jensen AT, Enevold A, Ronn AM, Khalil IF, Warhurst DC, Lemnge MM, Theander TG, Bygbjerg IC, , 2006. Occurrence of the southeast Asian/South American SVMNT haplotype of the chloroquine-resistance transporter gene in Plasmodium falciparum in Tanzania. J Infect Dis 193: 17381741.[Crossref]
  20. Dia I, Diop T, Rakotoarivony I, Kengne P, Fontenille D, , 2003. Bionomics of Anopheles gambiae Giles, An. arabiensis Patton, An. funestus Giles and An. nili (Theobald) (Diptera: Culicidae) and transmission of Plasmodium falciparum in a Sudano-Guinean zone (Ngari, Senegal). J Med Entomol 40: 279283.[Crossref]
  21. Wooden J, Kyes S, Sibley CH, , 1993. PCR and strain identification in Plasmodium falciparum . Parasitol Today 9: 303305.[Crossref]
  22. Pearce RJ, Drakeley C, Chandramohan D, Mosha F, Roper C, , 2003. Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania. Antimicrob Agents Chemother 47: 13471354.[Crossref]
  23. Wilson PE, Kazadi W, Kamwendo DD, Mwapasa V, Purfield A, Meshnick SR, , 2005. Prevalence of Pfcrt mutations in Congolese and Malawian Plasmodium falciparum isolates as determined by a new Taqman assay. Acta Trop 93: 97106.[Crossref]
  24. Hayton K, Su XZ, , 2004. Genetic and biochemical aspects of drug resistance in malaria parasites. Curr Drug Targets Infect Disord 4: 110.[Crossref]
  25. Alifrangis M, Enosse S, Pearce R, Drakeley C, Roper C, Khalil IF, Nkya WMMM, Ronn AM, Theander TG, Bygjerg IBC, , 2005. Simple, high-throughput method to detect Plasmodium falciparum single nucleotide polymorphisms in the dihydrofolate reductase, dihydropteroate synthase, and P. falciparum chloroquine resistance transporter genes using polymerase chain reaction- and enzyme-linked immunosorbent assay-based technology. Am J Trop Med Hyg 72: 155162.
  26. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, , 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359: 26192620.[Crossref]
  27. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ, , 2009. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455467.[Crossref]
  28. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimdé AA, Kouriba B, Taylor TE, Plowe CV, , 2003. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis 187: 18701875.[Crossref]
  29. Mwai L, Ochong E, Abdirahman A, Kiara SM, Ward S, Kokwaro G, Sasi P, Marsh K, Borrmann S, Mackinnon M, Nzila A, , 2009. Chloroquine resistance before and after its withdrawal in Kenya. Malar J 8: 106.[Crossref]
  30. Alifrangis M, Lusingu JP, Mmbando B, Dalgaard MB, Vestergaard LS, Ishengoma D, Khalil IF, Theander TG, Lemnge MM, Bygbjerg IC, , 2009. Five-year surveillance of molecular markers of Plasmodium falciparum antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the 581G mutation in the P. falciparum dihydropteroate synthase gene. Am J Trop Med Hyg 80: 523527.
  31. Mita T, Kaneko A, Lum JK, Bwijo B, Takechi N, Zungu IL, Tsukahara T, Tanabe K, Kobayakawa T, Bjorkman A, , 2003. Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. Am J Trop Med Hyg 68: 413415.
  32. Abdel-Muhsin AM, Mackinnon MJ, Ali E, Nassir el KA, Suleiman S, Ahmed S, Walliker D, Babiker HA, , 2004. Evolution of drug-resistance genes in Plasmodium falciparum in an area of seasonal malaria transmission in Eastern Sudan. J Infect Dis 189: 12391244.[Crossref]
  33. Henry M, Diallo I, Bordes J, Ka S, Pradines B, Diatta B, M'baye PS, Sane M, Thiam M, Gueye PM, Wade O, Touze JE, Debonne JM, Rogier C, Fusai T, , 2006. Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of Plasmodium falciparum isolates. Am J Trop Med Hyg 75: 146151.
  34. Sarr O, Myrick A, Daily J, Diop BM, Dieng T, Ndir O, Sow PS, Mboup S, Wirth DF, , 2005. In vivo and in vitro analysis of chloroquine resistance in Plasmodium falciparum isolates from Senegal. Parasitol Res 97: 136140.[Crossref]
  35. Sarr O, Ahouidi AD, Ly O, Daily JP, Ndiaye D, Ndir O, Mboup S, Wirth DF, , 2008. Mutations in PFCRT K76T do not correlate with sulfadoxine–pyrimethamine–amodiaquine failure in Pikine, Senegal. Parasitol Res 103: 765769.[Crossref]
  36. Ndiaye D, Patel V, Demas A, LeRoux M, Ndir O, Mboup S, Clardy J, Lakshmanan V, Daily JP, Wirth DF, , 2010. A non-radioactive DAPI-based high-throughput in vitro assay to assess Plasmodium falciparum responsiveness to antimalarials—increased sensitivity of P. falciparum to chloroquine in Senegal. Am J Trop Med Hyg 82: 228230.[Crossref]
  37. Ursing J, Kofoed PE, Rodrigues A, Rambo L, Gil JP, , 2007. Plasmodium falciparum genotypes associated with chloroquine and amodiaquine resistance in Guinea-bissau. Am J Trop Med Hyg 76: 844848.
  38. Frosch A, Venkatesan M, Laufer MK, , 2011. Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data. Malar J 10: 116.[Crossref]
  39. Sisowath C, Petersen I, Veiga MI, Mårtensson A, Premji Z, Björkman A, Fidock DA, Gil JP, , 2009. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible Pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis 199: 750755.[Crossref]
  40. Greenwood B, , 2006. Intermittent preventive treatment–a new approach to the prevention of malaria in children in areas with seasonal malaria transmission. Trop Med Int Health 11: 983991.[Crossref]
  41. Cissé B, Sokhna C, Boulanger D, Milet J, EH, Richardson K, Hallett R, Sutherland COL, Simondon K, Simondon F, Neal A, Gaye O, Targett G, Jo L, Greenwood B, Trape JF, , 2006. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet 367: 659667.[Crossref]
  42. Dicko A, Sagara I, Sissoko MS, Guindo O, Diallo A, Kone M, Toure OB, Sacko M, Doumbo O, , 2008. Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Malar J 7: 123.[Crossref]
  43. Sohna C, Cisse B, Ba EH, Milligan P, Hallett RA, Sutherland C, Gaye O, Boulanger D, Simondon K, Simondon F, Targett G, Lines J, Greenwood B, Trape JF, , 2009. A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. PLoS One 3: e1471.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2012.11-0709
Loading
/content/journals/10.4269/ajtmh.2012.11-0709
Loading

Data & Media loading...

  • Received : 14 Nov 2011
  • Accepted : 11 Jun 2012

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error